PortfoliosLab logoPortfoliosLab logo
CORT vs. META
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CORT vs. META - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Corcept Therapeutics Incorporated (CORT) and Meta Platforms, Inc. (META). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CORT achieves a 129.05% return, which is significantly higher than META's -14.42% return. Over the past 10 years, CORT has outperformed META with an annualized return of 31.34%, while META has yielded a comparatively lower 17.64% annualized return.


CORT

1D
-0.25%
1M
32.36%
YTD
129.05%
6M
-6.34%
1Y
11.67%
3Y*
53.92%
5Y*
29.06%
10Y*
31.34%

META

1D
-2.32%
1M
-7.51%
YTD
-14.42%
6M
-14.61%
1Y
-17.09%
3Y*
25.36%
5Y*
10.80%
10Y*
17.64%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CORT vs. META - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CORT
Corcept Therapeutics Incorporated
129.05%-30.94%55.14%59.92%2.58%-24.31%116.20%-9.43%-26.02%148.76%
META
Meta Platforms, Inc.
-14.42%13.09%66.05%194.13%-64.22%23.13%33.09%56.57%-25.71%53.38%

Correlation

The correlation between CORT and META is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.18

Correlation (3Y)
Calculated over the trailing 3-year period

0.21

Correlation (5Y)
Calculated over the trailing 5-year period

0.24

Correlation (10Y)
Calculated over the trailing 10-year period

0.24

Correlation (All Time)
Calculated using the full available price history since May 18, 2012

0.25

Fundamentals

Market Cap

CORT:

$8.32B

META:

$1.45T

EPS

CORT:

$0.41

META:

$27.47

PE Ratio

CORT:

194.37

META:

20.53

PEG Ratio

CORT:

96.82

META:

0.85

PS Ratio

CORT:

12.03

META:

6.74

PB Ratio

CORT:

13.05

META:

5.93

Total Revenue (TTM)

CORT:

$769.10M

META:

$214.96B

Gross Profit (TTM)

CORT:

$755.64M

META:

$176.14B

EBITDA (TTM)

CORT:

$3.66M

META:

$106.31B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CORT vs. META — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CORT
CORT Risk / Return Rank: 5050
Overall Rank
CORT Sharpe Ratio Rank: 4848
Sharpe Ratio Rank
CORT Sortino Ratio Rank: 4949
Sortino Ratio Rank
CORT Omega Ratio Rank: 6060
Omega Ratio Rank
CORT Calmar Ratio Rank: 4747
Calmar Ratio Rank
CORT Martin Ratio Rank: 4646
Martin Ratio Rank

META
META Risk / Return Rank: 2121
Overall Rank
META Sharpe Ratio Rank: 2121
Sharpe Ratio Rank
META Sortino Ratio Rank: 2020
Sortino Ratio Rank
META Omega Ratio Rank: 2020
Omega Ratio Rank
META Calmar Ratio Rank: 2424
Calmar Ratio Rank
META Martin Ratio Rank: 2020
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CORT vs. META - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Corcept Therapeutics Incorporated (CORT) and Meta Platforms, Inc. (META). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CORTMETADifference
Sharpe ratioReturn per unit of total volatility

+0.63

Sortino ratioReturn per unit of downside risk

+1.24

Omega ratioGain probability vs. loss probability

1.16

0.94

+0.22

Calmar ratioReturn relative to maximum drawdown

0.18

-0.52

+0.70

Martin ratioReturn relative to average drawdown

0.33

-1.04

+1.37

CORT vs. META - Sharpe Ratio Comparison

The current CORT Sharpe Ratio is 0.15, which is higher than the META Sharpe Ratio of -0.47. The chart below compares the historical Sharpe Ratios of CORT and META, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CORT vs. META - Drawdown Comparison

The maximum CORT drawdown since its inception was -94.29%, which is greater than META's maximum drawdown of -76.74%. Use the drawdown chart below to compare losses from any high point for CORT and META.


Loading charts...

Drawdown Indicators


CORTMETADifference

Max Drawdown

Largest peak-to-trough decline

-94.29%

-76.74%

-17.55%

Max Drawdown (1Y)

Largest decline over 1 year

-64.40%

-33.30%

-31.10%

Max Drawdown (3Y)

Largest decline over 3 years

-71.85%

-34.15%

-37.70%

Max Drawdown (5Y)

Largest decline over 5 years

-71.85%

-76.74%

+4.89%

Max Drawdown (10Y)

Largest decline over 10 years

-71.85%

-76.74%

+4.89%

Current Drawdown

Current decline from peak

-30.21%

-28.39%

-1.82%

Average Drawdown

Average peak-to-trough decline

-53.43%

-15.84%

-37.59%

Ulcer Index

Depth and duration of drawdowns from previous peaks

35.39%

16.48%

+18.91%

Volatility

CORT vs. META - Volatility Comparison

Corcept Therapeutics Incorporated (CORT) has a higher volatility of 13.61% compared to Meta Platforms, Inc. (META) at 12.93%. This indicates that CORT's price experiences larger fluctuations and is considered to be riskier than META based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CORTMETADifference

Volatility (1M)

Calculated over the trailing 1-month period

13.61%

12.93%

+0.68%

Volatility (6M)

Calculated over the trailing 6-month period

85.06%

27.95%

+57.11%

Volatility (1Y)

Calculated over the trailing 1-year period

77.18%

36.25%

+40.93%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

74.59%

44.18%

+30.41%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

67.22%

38.77%

+28.45%

Dividends

CORT vs. META - Dividend Comparison

CORT has not paid dividends to shareholders, while META's dividend yield for the trailing twelve months is around 0.38%.


PositionTTM20252024
CORT
Corcept Therapeutics Incorporated
0.00%0.00%0.00%
META
Meta Platforms, Inc.
0.38%0.32%0.34%

Financials

CORT vs. META - Financials Comparison

This section allows you to compare key financial metrics between Corcept Therapeutics Incorporated and Meta Platforms, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00B20.00B30.00B40.00B50.00B60.00B20222023202420252026
164.90M
56.31B
(CORT) Total Revenue
(META) Total Revenue
Values in USD except per share items

CORT vs. META - Profitability Comparison

The chart below illustrates the profitability comparison between Corcept Therapeutics Incorporated and Meta Platforms, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

75.0%80.0%85.0%90.0%95.0%100.0%20222023202420252026
98.3%
81.9%
Portfolio components
CORT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a gross profit of 162.02M and revenue of 164.90M. Therefore, the gross margin over that period was 98.3%.

META - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Meta Platforms, Inc. reported a gross profit of 46.09B and revenue of 56.31B. Therefore, the gross margin over that period was 81.9%.

CORT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported an operating income of -49.60M and revenue of 164.90M, resulting in an operating margin of -30.1%.

META - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Meta Platforms, Inc. reported an operating income of 22.87B and revenue of 56.31B, resulting in an operating margin of 40.6%.

CORT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a net income of -31.20M and revenue of 164.90M, resulting in a net margin of -18.9%.

META - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Meta Platforms, Inc. reported a net income of 26.77B and revenue of 56.31B, resulting in a net margin of 47.5%.


Frequently Asked Questions


CORT and META have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CORT has higher volatility (13.61%) compared to META (12.93%). In terms of maximum drawdown, CORT dropped -94.29% vs META's -76.74%.

CORT currently has the higher Sharpe Ratio (0.15 vs -0.47), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CORT and META

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer